We are pleased to share some encouraging news regarding the treatment landscape for those living with ADPKD. Today, Otsuka announced results from their Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). This data was presented at the American Society of Nephrology (ASN) Conference in New Orleans and published online in the New England Journal of Medicine.

The trial included participation from Canadian nephrologists and patients. Tolvaptan has been approved in Canada since February 2015 and now further data is available on the treatment.

“While tolvaptan is approved and available for Canadians, these new results further substantiate the benefits of this treatment for those living with ADPKD,” says Dr. Daniel G. Bichet, Faculty of Medicine, Université de Montréal and a Canadian investigator in the REPRISE trial. “This trial further supports the evidence that treatment with tolvaptan slows down kidney function loss, providing new hope to more patients with ADPKD.”

The findings from the trial’s results can be found at the link here.